May Measurement Month 2018: an analysis of blood pressure screening results from Colombia.
Blood pressure
Control
Hypertension
Screening
Treatment
Journal
European heart journal supplements : journal of the European Society of Cardiology
ISSN: 1520-765X
Titre abrégé: Eur Heart J Suppl
Pays: England
ID NLM: 100886647
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
entrez:
5
9
2020
pubmed:
5
9
2020
medline:
5
9
2020
Statut:
ppublish
Résumé
High blood pressure (BP) is the leading global preventable cause of death and the most common risk factor for cardiovascular disease (CVD). However, due to its asymptomatic nature, the lack of awareness of this condition causes underdiagnosis and low rates of adherence to pharmacological treatment. Looking for practical approaches to increase awareness worldwide, the International Society of Hypertension (ISH) implemented the 2nd May Measurement Month campaign in 2018 (MMM18). In order to contribute to this initiative, Colombia participated as one of the 89 countries involved in this hypertension screening programme. Blood pressure was measured in subjects from 11 departments in Colombia. Under the leadership of the Fundación Oftalmológica de Santander (FOSCAL), 400 volunteers across the country collected the data following the MMM protocol. Measurements from 35 548 participants with a mean age of 41.9 years were obtained. In total, 9475 (26.7%) of the total population studied had hypertension. Of those with hypertension, 69.9% of these subjects were aware of their condition, 65.0% were on antihypertensive medication, and 43.1% had controlled BP. Of those on medication, 66.3% had controlled BP. Hypertension screening, awareness, treatment, and control should be a priority in public health objectives due to its elevated burden of disease and direct association with increased CVD. The MMM campaign provided a positive impact in the diagnosis of hypertension across Colombia. Although efforts are being made to expand treatment capability and adherence, still more are needed to insure a broader coverage of antihypertensive medication in Colombia.
Identifiants
pubmed: 32884467
doi: 10.1093/eurheartj/suaa025
pii: suaa025
pmc: PMC7455303
doi:
Types de publication
Journal Article
Langues
eng
Pagination
H43-H46Informations de copyright
Published on behalf of the European Society of Cardiology. © The Author(s) 2020.
Références
Eur Heart J Suppl. 2019 Apr;21(Suppl D):D40-D43
pubmed: 31043874
Lancet. 2016 Nov 26;388(10060):2665-2712
pubmed: 27671667
Lancet. 2020 Mar 7;395(10226):795-808
pubmed: 31492503
J Hypertens. 2019 Jun;37(6):1126-1147
pubmed: 30882601
Eur Heart J. 2019 Jul 1;40(25):2092
pubmed: 31005984
Lancet. 2019 Oct 5;394(10205):1231-1242
pubmed: 31488369
Eur Heart J. 2019 Jul 1;40(25):2006-2017
pubmed: 31041440
Lancet. 2020 Mar 7;395(10226):785-794
pubmed: 31492501
J Am Coll Cardiol. 2015 Apr 7;65(13):1371-1372
pubmed: 25835450